Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In Cellular Therapy
Cellular Therapy for March/April 2019
Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9
Cellular Therapy for November/December 2018
Ixazomib improves PFS after myeloma transplant, Dimopoulos MA et al. ASH 2018, Abstract 301
HSCT performs well in scleroderma-related lung disease, Goldin J et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 901
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
Cellular Therapy for September/October 2018
Auto-HSCT plus ablation in severe scleroderma, Sullivan KM et al. ACR Annual Meeting, Abstract 1820
CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9
auto-FMT could help ease GVHD after transplant, Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489
Cellular Therapy for May/June 2018
Blood type is diarrhea destiny, Kumar P et al. J Clin Invest. 2018 May 17; doi: 10.1172/JCI97659.
Fertility poor irrespective of conditioning regimen for transplants , Oquendo del Toro H et al. The 2018 Bone Marrow Transplant Tandem Meetings, Abstract 88.
Comorbidity index reflects nonrelapse mortality for youths undergoing transplants, Friend B et al. ALF 2018, Poster Session.
Relapse triggers high rate of haploidentical donor graft failure, Yanir AD et al. Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2018.03.001.